Cargando…
Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies
Uveal melanoma (UM) is the most frequent ocular cancer in adults, accounting for ~5% of the total melanoma incidence. Although the primary tumor is well treatable, patients frequently develop metastases for which no curative therapy exists. Highly activated protein kinase C (PKC) is a common feature...
Autores principales: | Heijkants, R. C., Nieveen, M., Hart, K. C.’t, Teunisse, A. F. A. S., Jochemsen, A. G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874255/ https://www.ncbi.nlm.nih.gov/pubmed/29593251 http://dx.doi.org/10.1038/s41389-018-0041-y |
Ejemplares similares
-
Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma
por: Heijkants, Renier, et al.
Publicado: (2017) -
MDMX Regulates Transcriptional Activity of p53 and FOXO Proteins to Stimulate Proliferation of Melanoma Cells
por: Heijkants, Renier C., et al.
Publicado: (2022) -
Targeting Mdmx to treat breast cancers with wild-type p53
por: Haupt, S, et al.
Publicado: (2015) -
Novel Treatments of Uveal Melanoma Identified with a Synthetic Lethal CRISPR/Cas9 Screen
por: Glinkina, Kseniya, et al.
Publicado: (2022) -
Preclinical Evaluation of Trabectedin in Combination With Targeted Inhibitors for Treatment of Metastatic Uveal Melanoma
por: Glinkina, Kseniya, et al.
Publicado: (2022)